ADC Therapeutics outlines ZYNLONTA-focused growth and financing strategy

An update from ADC Therapeutics ( (ADCT) ) is now available.

On January 12, 2026, ADC Therapeutics released an updated corporate presentation highlighting its strategy to build growth around ZYNLONTA and strengthen its financial position following a year of portfolio derisking and cost restructuring in 2025. The company reported that preliminary full-year 2025 net revenue for ZYNLONTA was approximately $73 million, roughly in line with 2024, and detailed a strategic reprioritization that included discontinuation of its remaining solid-tumor preclinical pipeline, a roughly 30% global workforce reduction, and closure of its UK operations to concentrate resources on ZYNLONTA expansion. Clinical updates pointed to strong response rates in the LOTIS-7 trial and in investigator-initiated studies in FL and MZL, while financing activity raised about $160 million in equity and left the company with an estimated $261 million in cash and an expected runway extending at least to 2028, positioning it to pursue its ambition of establishing ZYNLONTA as a backbone therapy in DLBCL and indolent lymphomas and to target a substantial U.S. peak revenue opportunity.

The most recent analyst rating on (ADCT) stock is a Sell with a $3.50 price target. To see the full list of analyst forecasts on ADC Therapeutics stock, see the ADCT Stock Forecast page.

Spark’s Take on ADCT Stock

According to Spark, TipRanks’ AI Analyst, ADCT is a Neutral.

ADCT scores low primarily due to weak financial performance (declining revenue, large losses, ongoing cash burn, and negative equity). Technicals are also mildly bearish with negative MACD and price below key short/intermediate moving averages. These are partially offset by a more positive earnings outlook and corporate updates (extended cash runway and encouraging clinical data), but not enough to outweigh the current profitability and balance-sheet risks.

To see Spark’s full report on ADCT stock, click here.

More about ADC Therapeutics

ADC Therapeutics SA is a biotechnology company specializing in the development and commercialization of antibody-drug conjugates (ADCs) for hematologic malignancies. Its lead product, ZYNLONTA, is an FDA-approved therapy for diffuse large B-cell lymphoma (DLBCL), and the company is focused on expanding ZYNLONTA’s use as a backbone for combination therapies in earlier lines of DLBCL and in indolent lymphomas such as follicular lymphoma (FL) and marginal zone lymphoma (MZL), supported by in-house development, technical operations and commercial capabilities.

Average Trading Volume: 1,181,758

Technical Sentiment Signal: Buy

Current Market Cap: $442.2M

For an in-depth examination of ADCT stock, go to TipRanks’ Overview page.